Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction.
Eirini GiannoudakiYasmina E Hernandez SantanaKelly MulfaulSarah L DoyleEmily HamsPadraic G FallonArimin MatDonal O'SheaManfred KopfAndrew E HoganPatrick T WalshPublished in: Nature communications (2019)
Members of the interleukin-1 (IL-1) family are important mediators of obesity and metabolic disease and have been described to often play opposing roles. Here we report that the interleukin-36 (IL-36) subfamily can play a protective role against the development of disease. Elevated IL-36 cytokine expression is found in the serum of obese patients and negatively correlates with blood glucose levels among those presenting with type 2 diabetes. Mice lacking IL-36Ra, an IL-36 family signalling antagonist, develop less diet-induced weight gain, hyperglycemia and insulin resistance. These protective effects correlate with increased abundance of the metabolically protective bacteria Akkermansia muciniphila in the intestinal microbiome. IL-36 cytokines promote its outgrowth as well as increased colonic mucus secretion. These findings identify a protective role for IL-36 cytokines in obesity and metabolic disease, adding to the current understanding of the role the broader IL-1 family plays in regulating disease pathogenesis.
Keyphrases
- insulin resistance
- weight gain
- high fat diet induced
- metabolic syndrome
- type diabetes
- weight loss
- blood glucose
- obese patients
- bariatric surgery
- body mass index
- oxidative stress
- poor prognosis
- physical activity
- high fat diet
- skeletal muscle
- polycystic ovary syndrome
- gastric bypass
- idiopathic pulmonary fibrosis
- binding protein
- case report
- gestational age